Generic placeholder image

Current Signal Transduction Therapy

Editor-in-Chief

ISSN (Print): 1574-3624
ISSN (Online): 2212-389X

Mini-Review Article

Exploring the Evolving Significance of lncRNA TUG1-mediated Signaling Pathways in Breast Cancer

Author(s): Mahrokh Abouali Gale Dari, Amir Anbiyaiee, Mehdi Moghanibashi, Razieh Mohammad Jafari, Farideh Moramezi and Maryam Farzaneh*

Volume 19, Issue 1, 2024

Published on: 19 January, 2024

Article ID: e190124225822 Pages: 7

DOI: 10.2174/0115743624264761231212055008

Price: $65

Abstract

Breast cancer is one of the most common malignancies in women worldwide. Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most common kinds of invasive breast cancer. Several genetic, epigenetic, and environmental factors could trigger the pathogenesis of breast cancer. Breast cancer treatment generally includes surgery, radiation therapy, chemotherapy, hormonal treatment, targeted therapy, immunotherapeutic, neoadjuvant systemic therapy, and systemic therapy. Although several classical treatment methods are used in cancer therapy, molecular-based strategies can open a new perspective for breast cancer treatment. Previous studies reported that long non-coding RNAs (lncRNAs) play important roles in cancer development and progression. LncRNA TUG1 was found to target several miRNAs and regulate breast cancer cell behavior. TUG1 can induce cell proliferation and invasion of breast cancer cells via downregulation of some miRNAs. Therefore, TUG1 might be a potent biomarker for the treatment of human cancer. In this review, we summarized the functional roles of TUG1 in breast cancer.

Keywords: LncRNAs, TUG1, breast cancer, biomarker, diagnosis, surgery, radiation therapy.

Graphical Abstract
[1]
Taha Z, Eltom SE. The role of diet and lifestyle in women with breast cancer: an update review of related research in the Middle East. Biores Open Access 2018; 7(1): 73-80.
[http://dx.doi.org/10.1089/biores.2018.0004] [PMID: 29862141]
[2]
Natarajan R, Aljaber D, Au D, et al. Environmental exposures during puberty: Window of breast cancer risk and epigenetic damage. Int J Environ Res Public Health 2020; 17(2): 493.
[http://dx.doi.org/10.3390/ijerph17020493] [PMID: 31941024]
[3]
Shaw BM, Kis O. Hereditary Cancer Syndromes and Cancer. Cancer Metastasis Through the Lymphovascular System 2022; pp. 37-52.
[4]
Kashyap D, Pal D, Sharma R, et al. Global increase in breast cancer incidence: Risk factors and preventive measures. BioMed Res Int 2022; 2022: 1-16.
[http://dx.doi.org/10.1155/2022/9605439] [PMID: 35480139]
[5]
Teo TWSAD, Abdullah B, Zainol NZNB, Nayan NHBM, Muhammad NB. A systematic literature review: The effect of date palms (Phoenix dactylifera) toward Breast Cancer MCF-7 Cell Line. Ann Rom Soc Cell Biol 2021; 5387-93.
[6]
Hashemi SM, Rafiemanesh H, Aghamohammadi T, et al. Prevalence of anxiety among breast cancer patients: A systematic review and meta-analysis. Breast Cancer 2020; 27(2): 166-78.
[http://dx.doi.org/10.1007/s12282-019-01031-9] [PMID: 31828585]
[7]
Ren W, Chen M, Qiao Y, Zhao F. Global guidelines for breast cancer screening: A systematic review. Breast 2022; 64: 85-99.
[http://dx.doi.org/10.1016/j.breast.2022.04.003] [PMID: 35636342]
[8]
De La Cruz LM, Thiruchelvam PTR, Shivani J, Trina J, Blankenship SA, Fisher CS. Saving the male breast: A systematic literature review of breast-conservation surgery for male breast cancer. Ann Surg Oncol 2019; 26(12): 3939-44.
[http://dx.doi.org/10.1245/s10434-019-07588-1] [PMID: 31250345]
[9]
Mascara M, Constantinou C. Global perceptions of women on breast cancer and barriers to screening. Curr Oncol Rep 2021; 23(7): 74.
[http://dx.doi.org/10.1007/s11912-021-01069-z] [PMID: 33937940]
[10]
Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health 2019; 9(4): 217-22.
[http://dx.doi.org/10.2991/jegh.k.191008.001] [PMID: 31854162]
[11]
Buhagiar A, Seria E, Borg M, Borg J, Ayers D. Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance. Cancer Drug Resist 2021; 4(4): 934-45.
[http://dx.doi.org/10.20517/cdr.2021.62] [PMID: 35582382]
[12]
De Silva S, Tennekoon KH, Karunanayake EH. Overview of the genetic basis toward early detection of breast cancer. Breast Cancer 2019; 11: 71-80.
[http://dx.doi.org/10.2147/BCTT.S185870] [PMID: 30718964]
[13]
Lips EH, Kumar T, Megalios A, et al. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nat Genet 2022; 54(6): 850-60.
[http://dx.doi.org/10.1038/s41588-022-01082-3] [PMID: 35681052]
[14]
Ho W-K, Tai M-C, Dennis J, et al. Polygenic risk scores for prediction of breast cancer risk in Asian populations. Genetics in medicine: official journal of the American College of Medical Genetics 2022; 24: 586-600.
[http://dx.doi.org/10.1016/j.gim.2021.11.008]
[15]
Watkins EJ. Overview of breast cancer. JAAPA 2019; 32(10): 13-7.
[http://dx.doi.org/10.1097/01.JAA.0000580524.95733.3d] [PMID: 31513033]
[16]
da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG, de Melo AC. Triple negative breast cancer: A thorough review of biomarkers. Crit Rev Oncol Hematol 2020; 145: 102855.
[http://dx.doi.org/10.1016/j.critrevonc.2019.102855] [PMID: 31927455]
[17]
Howard FM, Pearson AT, Nanda R. Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2022; 195(1): 1-15.
[http://dx.doi.org/10.1007/s10549-022-06665-6] [PMID: 35834065]
[18]
Hester RH, Hortobagyi GN, Lim B. Inflammatory breast cancer: Early recognition and diagnosis is critical. Am J Obstet Gynecol 2021; 225(4): 392-6.
[http://dx.doi.org/10.1016/j.ajog.2021.04.217] [PMID: 33845027]
[19]
Fahad Ullah M. Breast cancer: Current perspectives on the disease status. Breast Cancer Metastasis and Drug Resistance 2019; pp. 51-64.
[20]
Loo SK, Yates ME, Yang S, Oesterreich S, Lee AV, Wang XS. Fusion‐associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance. Genes Chromosomes Cancer 2022; 61(5): 261-73.
[http://dx.doi.org/10.1002/gcc.23029] [PMID: 35106856]
[21]
Rautela K, Kumar D, Kumar V. A systematic review on breast cancer detection using deep learning techniques. Arch Comput Methods Eng 2022; 29(7): 4599-629.
[http://dx.doi.org/10.1007/s11831-022-09744-5]
[22]
Hamid AB, Frank LE, Bouley RA, Petreaca RC. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers. PLoS One 2022; 17(9): e0273736.
[http://dx.doi.org/10.1371/journal.pone.0273736] [PMID: 36107942]
[23]
Huber-Keener KJ. Cancer genetics and breast cancer. Best Pract Res Clin Obstet Gynaecol 2022; 82: 3-11.
[http://dx.doi.org/10.1016/j.bpobgyn.2022.01.007] [PMID: 35272929]
[24]
Thakur C, Qiu Y, Fu Y, et al. Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies. Front Oncol 2022; 12: 971288.
[http://dx.doi.org/10.3389/fonc.2022.971288] [PMID: 36185256]
[25]
Bohm MS, Sipe LM, Pye ME, Davis MJ, Pierre JF, Makowski L. The role of obesity and bariatric surgery-induced weight loss in breast cancer. Cancer Metastasis Rev 2022; 41(3): 673-95.
[http://dx.doi.org/10.1007/s10555-022-10050-6] [PMID: 35870055]
[26]
Vo AT, Millis RM. Epigenetics and breast cancers. Obstet Gynecol Int 2012; 2012: 1-10.
[http://dx.doi.org/10.1155/2012/602720] [PMID: 22567014]
[27]
Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 2018; 5(2): 77-106.
[http://dx.doi.org/10.1016/j.gendis.2018.05.001] [PMID: 30258937]
[28]
Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci 2017; 13(11): 1387-97.
[http://dx.doi.org/10.7150/ijbs.21635] [PMID: 29209143]
[29]
Gandhi S, Brackstone M, Hong NJL, et al. A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. Breast Cancer Res Treat 2022; 193(1): 1-20.
[http://dx.doi.org/10.1007/s10549-022-06522-6] [PMID: 35224713]
[30]
Carleton N, Nasrazadani A, Gade K, et al. Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women. Lancet Healthy Longev 2022; 3(1): e54-66.
[http://dx.doi.org/10.1016/S2666-7568(21)00280-4] [PMID: 35047868]
[31]
Guillen KP, Fujita M, Butterfield AJ, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Can 2022; 3(2): 232-50.
[http://dx.doi.org/10.1038/s43018-022-00337-6] [PMID: 35221336]
[32]
Magnoni F, Sacchini V, Veronesi P, et al. Surgical management of inherited breast cancer: Role of breast-conserving surgery. Cancers 2022; 14(13): 3245.
[http://dx.doi.org/10.3390/cancers14133245] [PMID: 35805017]
[33]
Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer 2022; 22(6): 323-39.
[http://dx.doi.org/10.1038/s41568-022-00454-5] [PMID: 35264777]
[34]
Lau KH, Tan AM, Shi Y. New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci 2022; 23(4): 2288.
[http://dx.doi.org/10.3390/ijms23042288] [PMID: 35216405]
[35]
Xu WW, Jin J, Wu X, Ren QL, Farzaneh M. MALAT1-related signaling pathways in colorectal cancer. Cancer Cell Int 2022; 22(1): 126.
[http://dx.doi.org/10.1186/s12935-022-02540-y] [PMID: 35305641]
[36]
Duan W, Nian L, Qiao J, Liu NN. LncRNA TUG1 aggravates the progression of cervical cancer by binding PUM2. Eur Rev Med Pharmacol Sci 2019; 23(19): 8211-8.
[PMID: 31646551]
[37]
Zhou H, Sun L, Wan F. Molecular mechanisms of TUG1 in the proliferation, apoptosis, migration and invasion of cancer cells (Review). Oncol Lett 2019; 18(5): 4393-402.
[http://dx.doi.org/10.3892/ol.2019.10848] [PMID: 31611948]
[38]
Bencivenga D, Stampone E, Vastante A, Barahmeh M, Della Ragione F, Borriello A. An unanticipated modulation of cyclin-dependent kinase inhibitors: The role of long non-coding RNAs. Cells 2022; 11(8): 1346.
[http://dx.doi.org/10.3390/cells11081346] [PMID: 35456025]
[39]
Zhang E, He X, Yin D, et al. Increased expression of long noncoding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57. Cell Death Dis 2016; 7(2): e2109-9.
[http://dx.doi.org/10.1038/cddis.2015.356] [PMID: 26913601]
[40]
Zilio N, Codlin S, Vashisht AA, et al. A novel histone deacetylase complex in the control of transcription and genome stability. Mol Cell Biol 2014; 34(18): 3500-14.
[http://dx.doi.org/10.1128/MCB.00519-14] [PMID: 25002536]
[41]
Sun J, Ding C, Yang Z, et al. The long non-coding RNA TUG1 indicates a poor prognosis for colorectal cancer and promotes metastasis by affecting epithelial-mesenchymal transition. J Transl Med 2016; 14(1): 42.
[http://dx.doi.org/10.1186/s12967-016-0786-z] [PMID: 26856330]
[42]
Wang H, Liao S, Li H, Chen Y, Yu J. Long Non-coding RNA TUG1 Sponges Mir-145a-5p to regulate microglial polarization after oxygen-glucose deprivation. Front Mol Neurosci 2019; 12: 215-5.
[http://dx.doi.org/10.3389/fnmol.2019.00215] [PMID: 31551710]
[43]
Azizidoost S, Farzaneh M. MicroRNAs as a novel player for differentiation of mesenchymal stem cells into cardiomyocytes. Curr Stem Cell Res Ther 2022.
[PMID: 35466882]
[44]
Ying H, Ebrahimi M, Keivan M, Khoshnam SE, Salahi S, Farzaneh M. miRNAs; a novel strategy for the treatment of COVID‐19. Cell Biol Int 2021; 45(10): 2045-53.
[http://dx.doi.org/10.1002/cbin.11653] [PMID: 34180562]
[45]
Alkhathami AG, Hadi A, Alfaifi M, Alshahrani MY, Verma AK, Beg MMA. Serum-Based lncRNA ANRIL, TUG1, UCA1, and HIT Expressions in Breast Cancer Patients. Dis Markers 2022; 2022: 1-11.
[http://dx.doi.org/10.1155/2022/9997212] [PMID: 35132340]
[46]
Zhao X, Ren G. LncRNA Taurine-Upregulated Gene 1 promotes cell proliferation by inhibiting microRNA-9 in MCF-7 Cells. J Breast Cancer 2016; 19(4): 349-57.
[http://dx.doi.org/10.4048/jbc.2016.19.4.349] [PMID: 28053623]
[47]
Fan S, Yang Z, Ke Z, et al. Downregulation of the long non-coding RNA TUG1 is associated with cell proliferation, migration, and invasion in breast cancer. Biomed Pharmacother 2017; 95: 1636-43.
[http://dx.doi.org/10.1016/j.biopha.2017.09.076] [PMID: 28950664]
[48]
Li T, Liu Y, Xiao H, Xu G. Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer. Breast Cancer 2017; 24(4): 535-43.
[http://dx.doi.org/10.1007/s12282-016-0736-x] [PMID: 27848085]
[49]
Tang T, Cheng Y, She Q, et al. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer. Biomed Pharmacother 2018; 107: 338-46.
[http://dx.doi.org/10.1016/j.biopha.2018.07.076] [PMID: 30098551]
[50]
Wang S, Cheng M, Zheng X, et al. Interactions between lncRNA TUG1 and miR-9-5p modulate the resistance of breast cancer cells to doxorubicin by regulating eIF5A2. OncoTargets Ther 2020; 13: 13159-70.
[http://dx.doi.org/10.2147/OTT.S255113] [PMID: 33380806]
[51]
Azzam HN, El-Derany MO, Wahdan SA, Faheim RM, Helal GK, El-Demerdash E. Metabolic/hypoxial axis predicts tamoxifen resistance in breast cancer. Sci Rep 2022; 12(1): 16118.
[http://dx.doi.org/10.1038/s41598-022-19977-w] [PMID: 36167713]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy